APO Research
Talk to an analyst

APO RESEARCH · REPORT

COVID-19 Drug API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global COVID-19 Drug API Market Outlook and Growth Opportunities 2026

19 December 2025192 pages

Choose your research edition.

Industry ResearchCOVID-19 Drug API Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal COVID-19 Drug API Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal COVID-19 Drug API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal COVID-19 Drug API Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal COVID-19 Drug API Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global COVID-19 Drug API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for COVID-19 Drug API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for COVID-19 Drug API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for COVID-19 Drug API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the COVID-19 Drug API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the COVID-19 Drug API market include Chongqing Kangle Pharmaceutical Co., Ltd., Fuan Pharmaceutical Group, Wuhan Wuyao Pharmaceutical Co., Ltd, Cinkate, Shanghai Zhongxi Sunve Pharma Co., Ltd. and Shenhua Pharmaceutical Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global COVID-19 Drug API market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of COVID-19 Drug API and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents COVID-19 Drug API revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global COVID-19 Drug API market.

COVID-19 Drug API Segment by Company

Chongqing Kangle Pharmaceutical Co., Ltd.

Fuan Pharmaceutical Group

Wuhan Wuyao Pharmaceutical Co., Ltd

Cinkate

Shanghai Zhongxi Sunve Pharma Co., Ltd.

Shenhua Pharmaceutical Co., Ltd

COVID-19 Drug API Segment by Type

Hydroxychloroquine

Chloroquine Phosphate

Others

COVID-19 Drug API Segment by Application

Tablet

Injection

COVID-19 Drug API Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global COVID-19 Drug API status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the COVID-19 Drug API key companies, revenue, market share, and recent developments.

3. To split the COVID-19 Drug API breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions COVID-19 Drug API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify COVID-19 Drug API significant trends, drivers, influence factors in global and regions.

6. To analyze COVID-19 Drug API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global COVID-19 Drug API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of COVID-19 Drug API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of COVID-19 Drug API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global COVID-19 Drug API industry.

Chapter 3: Detailed analysis of COVID-19 Drug API company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of COVID-19 Drug API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of COVID-19 Drug API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. COVID-19 Drug API Industry Trends Table 2. COVID-19 Drug API Industry Drivers Table 3. COVID-19 Drug API Industry Opportunities and Challenges Table 4. COVID-19 Drug API Industry Restraints Table 5. Global COVID-19 Drug API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global COVID-19 Drug API Revenue Share by Company (2021-2026) Table 7. Global COVID-19 Drug API Company Ranking, (2024-2026) & (US$ Million) Table 8. Global COVID-19 Drug API Key Company Manufacturing Base & Headquarters Table 9. Global COVID-19 Drug API Company, Product Type & Application Table 10. Global COVID-19 Drug API Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global COVID-19 Drug API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hydroxychloroquine Table 15. Significant Companies of Chloroquine Phosphate Table 16. Significant Companies of Others Table 17. Global COVID-19 Drug API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global COVID-19 Drug API Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global COVID-19 Drug API Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global COVID-19 Drug API Sales Value Share by Type (2021-2026) Table 21. Global COVID-19 Drug API Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Tablet Table 23. Significant Companies of Injection Table 24. Global COVID-19 Drug API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global COVID-19 Drug API Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global COVID-19 Drug API Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global COVID-19 Drug API Sales Value Share by Application (2021-2026) Table 28. Global COVID-19 Drug API Sales Value Share by Application (2027-2032) Table 29. Global COVID-19 Drug API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global COVID-19 Drug API Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global COVID-19 Drug API Sales Value Share by Region (2021-2026) Table 32. Global COVID-19 Drug API Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global COVID-19 Drug API Sales Value Share by Region (2027-2032) Table 34. Global COVID-19 Drug API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global COVID-19 Drug API Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global COVID-19 Drug API Sales Value Market Share by Country (2021-2026) Table 37. Global COVID-19 Drug API Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global COVID-19 Drug API Sales Value Market Share by Country (2027-2032) Table 39. Chongqing Kangle Pharmaceutical Co., Ltd. Company Information Table 40. Chongqing Kangle Pharmaceutical Co., Ltd. Business Overview Table 41. Chongqing Kangle Pharmaceutical Co., Ltd. COVID-19 Drug API Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Chongqing Kangle Pharmaceutical Co., Ltd. COVID-19 Drug API Product Portfolio Table 43. Chongqing Kangle Pharmaceutical Co., Ltd. Recent Development Table 44. Fuan Pharmaceutical Group Company Information Table 45. Fuan Pharmaceutical Group Business Overview Table 46. Fuan Pharmaceutical Group COVID-19 Drug API Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Fuan Pharmaceutical Group COVID-19 Drug API Product Portfolio Table 48. Fuan Pharmaceutical Group Recent Development Table 49. Wuhan Wuyao Pharmaceutical Co., Ltd Company Information Table 50. Wuhan Wuyao Pharmaceutical Co., Ltd Business Overview Table 51. Wuhan Wuyao Pharmaceutical Co., Ltd COVID-19 Drug API Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Wuhan Wuyao Pharmaceutical Co., Ltd COVID-19 Drug API Product Portfolio Table 53. Wuhan Wuyao Pharmaceutical Co., Ltd Recent Development Table 54. Cinkate Company Information Table 55. Cinkate Business Overview Table 56. Cinkate COVID-19 Drug API Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Cinkate COVID-19 Drug API Product Portfolio Table 58. Cinkate Recent Development Table 59. Shanghai Zhongxi Sunve Pharma Co., Ltd. Company Information Table 60. Shanghai Zhongxi Sunve Pharma Co., Ltd. Business Overview Table 61. Shanghai Zhongxi Sunve Pharma Co., Ltd. COVID-19 Drug API Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Shanghai Zhongxi Sunve Pharma Co., Ltd. COVID-19 Drug API Product Portfolio Table 63. Shanghai Zhongxi Sunve Pharma Co., Ltd. Recent Development Table 64. Shenhua Pharmaceutical Co., Ltd Company Information Table 65. Shenhua Pharmaceutical Co., Ltd Business Overview Table 66. Shenhua Pharmaceutical Co., Ltd COVID-19 Drug API Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Shenhua Pharmaceutical Co., Ltd COVID-19 Drug API Product Portfolio Table 68. Shenhua Pharmaceutical Co., Ltd Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. COVID-19 Drug API Product Image Figure 2. Global COVID-19 Drug API Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global COVID-19 Drug API Market Size (2021-2032) & (US$ Million) Figure 4. Global COVID-19 Drug API Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hydroxychloroquine Image Figure 8. Chloroquine Phosphate Image Figure 9. Others Image Figure 10. Global COVID-19 Drug API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global COVID-19 Drug API Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global COVID-19 Drug API Sales Value Share by Type (2021-2032) Figure 13. Tablet Image Figure 14. Injection Image Figure 15. Global COVID-19 Drug API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global COVID-19 Drug API Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global COVID-19 Drug API Sales Value Share by Application (2021-2032) Figure 18. Global COVID-19 Drug API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global COVID-19 Drug API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America COVID-19 Drug API Sales Value (2021-2032) & (US$ Million) Figure 21. North America COVID-19 Drug API Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe COVID-19 Drug API Sales Value (2021-2032) & (US$ Million) Figure 23. Europe COVID-19 Drug API Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific COVID-19 Drug API Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific COVID-19 Drug API Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America COVID-19 Drug API Sales Value (2021-2032) & (US$ Million) Figure 27. South America COVID-19 Drug API Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa COVID-19 Drug API Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa COVID-19 Drug API Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt COVID-19 Drug API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Hydroxychloroquine
  • Chloroquine Phosphate
  • Others
Applications
  • Tablet
  • Injection
Companies covered
  • Chongqing Kangle Pharmaceutical Co., Ltd.
  • Fuan Pharmaceutical Group
  • Wuhan Wuyao Pharmaceutical Co., Ltd
  • Cinkate
  • Shanghai Zhongxi Sunve Pharma Co., Ltd.
  • Shenhua Pharmaceutical Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global COVID-19 Drug API Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global COVID-19 Drug API Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 COVID-19 Drug API Market Dynamics
  1. 2.1 COVID-19 Drug API Industry Trends
  2. 2.2 COVID-19 Drug API Industry Drivers
  3. 2.3 COVID-19 Drug API Industry Opportunities and Challenges
  4. 2.4 COVID-19 Drug API Industry Restraints
3 COVID-19 Drug API Market by Company
  1. 3.1 Global COVID-19 Drug API Company Revenue Ranking in 2025
  2. 3.2 Global COVID-19 Drug API Revenue by Company (2021-2026)
  3. 3.3 Global COVID-19 Drug API Company Ranking (2024-2026)
  4. 3.4 Global COVID-19 Drug API Company Manufacturing Base and Headquarters
  5. 3.5 Global COVID-19 Drug API Company Product Type and Application
  6. 3.6 Global COVID-19 Drug API Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global COVID-19 Drug API Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 COVID-19 Drug API Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 COVID-19 Drug API Market by Type
  1. 4.1 COVID-19 Drug API Type Introduction
  2. 4.1.1 Hydroxychloroquine
  3. 4.1.2 Chloroquine Phosphate
  4. 4.1.3 Others
  5. 4.2 Global COVID-19 Drug API Sales Value by Type
  6. 4.2.1 Global COVID-19 Drug API Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global COVID-19 Drug API Sales Value by Type (2021-2032)
  8. 4.2.3 Global COVID-19 Drug API Sales Value Share by Type (2021-2032)
5 COVID-19 Drug API Market by Application
  1. 5.1 COVID-19 Drug API Application Introduction
  2. 5.1.1 Tablet
  3. 5.1.2 Injection
  4. 5.2 Global COVID-19 Drug API Sales Value by Application
  5. 5.2.1 Global COVID-19 Drug API Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global COVID-19 Drug API Sales Value by Application (2021-2032)
  7. 5.2.3 Global COVID-19 Drug API Sales Value Share by Application (2021-2032)
6 COVID-19 Drug API Regional Value Analysis
  1. 6.1 Global COVID-19 Drug API Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global COVID-19 Drug API Sales Value by Region (2021-2032)
  3. 6.2.1 Global COVID-19 Drug API Sales Value by Region: 2021-2026
  4. 6.2.2 Global COVID-19 Drug API Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America COVID-19 Drug API Sales Value (2021-2032)
  7. 6.3.2 North America COVID-19 Drug API Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe COVID-19 Drug API Sales Value (2021-2032)
  10. 6.4.2 Europe COVID-19 Drug API Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific COVID-19 Drug API Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific COVID-19 Drug API Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America COVID-19 Drug API Sales Value (2021-2032)
  16. 6.6.2 South America COVID-19 Drug API Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa COVID-19 Drug API Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa COVID-19 Drug API Sales Value Share by Country, 2025 VS 2032
7 COVID-19 Drug API Country-level Value Analysis
  1. 7.1 Global COVID-19 Drug API Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global COVID-19 Drug API Sales Value by Country (2021-2032)
  3. 7.2.1 Global COVID-19 Drug API Sales Value by Country (2021-2026)
  4. 7.2.2 Global COVID-19 Drug API Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt COVID-19 Drug API Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt COVID-19 Drug API Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt COVID-19 Drug API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing Kangle Pharmaceutical Co., Ltd.
  2. 8.1.1 Chongqing Kangle Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Chongqing Kangle Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Chongqing Kangle Pharmaceutical Co., Ltd. COVID-19 Drug API Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing Kangle Pharmaceutical Co., Ltd. COVID-19 Drug API Product Portfolio
  6. 8.1.5 Chongqing Kangle Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Fuan Pharmaceutical Group
  8. 8.2.1 Fuan Pharmaceutical Group Company Information
  9. 8.2.2 Fuan Pharmaceutical Group Business Overview
  10. 8.2.3 Fuan Pharmaceutical Group COVID-19 Drug API Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Fuan Pharmaceutical Group COVID-19 Drug API Product Portfolio
  12. 8.2.5 Fuan Pharmaceutical Group Recent Developments
  13. 8.3 Wuhan Wuyao Pharmaceutical Co., Ltd
  14. 8.3.1 Wuhan Wuyao Pharmaceutical Co., Ltd Company Information
  15. 8.3.2 Wuhan Wuyao Pharmaceutical Co., Ltd Business Overview
  16. 8.3.3 Wuhan Wuyao Pharmaceutical Co., Ltd COVID-19 Drug API Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Wuhan Wuyao Pharmaceutical Co., Ltd COVID-19 Drug API Product Portfolio
  18. 8.3.5 Wuhan Wuyao Pharmaceutical Co., Ltd Recent Developments
  19. 8.4 Cinkate
  20. 8.4.1 Cinkate Company Information
  21. 8.4.2 Cinkate Business Overview
  22. 8.4.3 Cinkate COVID-19 Drug API Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Cinkate COVID-19 Drug API Product Portfolio
  24. 8.4.5 Cinkate Recent Developments
  25. 8.5 Shanghai Zhongxi Sunve Pharma Co., Ltd.
  26. 8.5.1 Shanghai Zhongxi Sunve Pharma Co., Ltd. Company Information
  27. 8.5.2 Shanghai Zhongxi Sunve Pharma Co., Ltd. Business Overview
  28. 8.5.3 Shanghai Zhongxi Sunve Pharma Co., Ltd. COVID-19 Drug API Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Zhongxi Sunve Pharma Co., Ltd. COVID-19 Drug API Product Portfolio
  30. 8.5.5 Shanghai Zhongxi Sunve Pharma Co., Ltd. Recent Developments
  31. 8.6 Shenhua Pharmaceutical Co., Ltd
  32. 8.6.1 Shenhua Pharmaceutical Co., Ltd Company Information
  33. 8.6.2 Shenhua Pharmaceutical Co., Ltd Business Overview
  34. 8.6.3 Shenhua Pharmaceutical Co., Ltd COVID-19 Drug API Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shenhua Pharmaceutical Co., Ltd COVID-19 Drug API Product Portfolio
  36. 8.6.5 Shenhua Pharmaceutical Co., Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst